Wiest Reiner
Department of Internal Medicine I, University Regensburg, Bavaria, Germany.
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S272-87. doi: 10.1097/MCG.0b013e318157cb57.
Experimental models are a sine qua non condition for unraveling the specific components and mechanisms contributing to vascular dysfunction and arterial vasodilation in portal hypertension. Moreover, a careful selection of the type of animal model, vascular bed, and methodology is crucial for any investigation of this issue. In this review, some critical aspects related to experimental models in portal hypertension and the techniques applied are highlighted. In addition, a detailed summary of the mechanisms of arterial vasodilation in portal hypertension is presented. First, humoral and endothelial vasodilators, predominantly nitric oxide but also carbon monoxide and endothelium-derived hyperpolarizing factor, and others are discussed. Second, time course and potential stimuli triggering and/or perpetuating splanchnic vasodilation are delineated. Finally, a brief general overview of vascular smooth muscle signaling sets the stage for a discussion on cotransmission, receptor desensitization, and the observed impairment in vasoconstrictor-induced smooth muscle contraction in the splanchnic and systemic circulation during portal hypertension.
实验模型是阐明门静脉高压症中导致血管功能障碍和动脉血管舒张的特定组成部分及机制的必要条件。此外,仔细选择动物模型的类型、血管床和方法对于该问题的任何研究都至关重要。在本综述中,强调了与门静脉高压症实验模型及应用技术相关的一些关键方面。此外,还对门静脉高压症中动脉血管舒张的机制进行了详细总结。首先,讨论了体液和内皮血管舒张剂,主要是一氧化氮,但也包括一氧化碳和内皮衍生的超极化因子等。其次,描述了触发和/或维持内脏血管舒张的时间进程和潜在刺激因素。最后,对血管平滑肌信号传导的简要概述为讨论共传递、受体脱敏以及门静脉高压症期间内脏和体循环中血管收缩剂诱导的平滑肌收缩所观察到的损伤奠定了基础。